Edition:
United States

Ventripoint Diagnostics Ltd (VPT.V)

VPT.V on TSX Venture Exchange

0.17CAD
21 Jul 2016
Change (% chg)

-- (--)
Prev Close
$0.17
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
24,449
52-wk High
$0.70
52-wk Low
$0.12

Summary

Name Age Since Current Position

George Adams

2010 President, Chief Executive Officer, Director

Ellen Briant

2013 Chief Financial Officer

Alan Rabinowitz

2014 Director

Donald Segal

68 2016 Director

David Willis

2015 Director

Danny Dalla-Longa

2005 Independent Director

Biographies

Name Description

George Adams

Dr. George Adams serves as President, Chief Executive Officer, Director of VentriPoint Diagnostics Ltd. Dr. Adams has partnered with Baxter, World Heart, Dupont, Corvita, Pfizer and Boston Scientific over the last 30 years to develop and commercialize diagnostic and medical device innovations. He has also been a founding director of 10 venture capital funds and 10 start-up companies, including two Canadian and one U.S. which have been publicly traded. From 2005 to 2010, he served as President and CEO of Amorfix Life Sciences Ltd. and prior thereto, he was the CEO of the University of Toronto Innovations Foundation. He is currently Chairman of the Board for Sernova Corporation. Dr. Adams obtained his Ph.D. from McMaster University.

Ellen Briant

Ms. Ellen Briant has been appointed as Chief Financial Officer of VentriPoint Diagnostics Ltd. Ms. Briant obtained a B.A. from Queen's University, a B.Comm. from the University of Windsor, and a M.B.A. from the Richard Ivey School of Business at the University of Western Ontario. As well, she earned the designation of Chartered Accountant (C.A.) from The Institute of Chartered Accountants of Ontario. Ms. Briant is a seasoned finance professional with 15 years of experience in corporate finance, project finance, banking, relationship management and accounting.

Alan Rabinowitz

Dr. Alan Rabinowitz has been appointed as Director of Ventripoint Diagnostics Ltd., with effect from 4 December 2014. Dr. Alan Rabinowitz is a cardiologist and President of the Medical Staff of St. Paul's Hospital, Vancouver, and Clinical Associate Professor in the Division of Cardiology at the University of British Columbia. He is the co-founder of PHEMI Health Systems and serves as Chief Medical Officer and a Director on the Board of that company. Dr. Rabinowitz received his medical degree from the University of Cape Town, South Africa, completed his internal medicine and cardiology training at the University of Toronto and undertook subsequent training in interventional cardiology at St. Paul's Hospital. In his previous capacity as Director of the Coronary Care Unit at St Paul's Hospital, Dr Rabinowitz recognized the critical importance of disruptive data solutions in transforming healthcare to enhance patient care, research and innovation, and improve sustainability of the healthcare ecosystem.

Donald Segal

Dr. Donald H. Segal is Director of the company. He is an entrepreneur with a successful history starting companies both in the private and public sector. With approximately 40 years of experience in the health care industry, he has managed several start-up companies through to commercialization. He is currently the chairman and CEO of United Biopharmaceuticals Inc. Previously he founded Joldon Diagnostics and spearheaded its amalgamation with Intercon Pharma and Helix Biotech to form Helix BioPharma Corp., where he was chairman and CEO. During his tenure, the company was listed on the TSX and NYSE and raised significant funding from capital markets to support product development. Dr. Segal's first company was Radioimmunoassay Inc. (RIA Inc.), which was sold as a private company. Dr. Segal has a PhD in medical sciences from the University of Guelph.

David Willis

Mr. Dave Willis is Director of the Company. Mr. Willis is an expert in the development and international sales of ultrasound equipment. Until recently, he was vice-president, competitive strategy and product innovation, at SonoSite-Fujifilm Ultrasound, where he was responsible for design input, launch and global training of four major product releases. He also served as vice-president of sales and marketing, the Americas, for Ultrasonix Medical Corp., where he managed sales forces in Canada, the United States and South America. Mr. Willis had been with SonoSite Ultrasound previously as vice-president of the general imaging business unit, where he helped grow sales to $65-million, and as director of product marketing. In the 1990s, he had positions with ATL Ultrasound as director of clinical marketing, manager of clinical investigations, senior clinical specialist, international sales specialist and applications specialist, where he managed a distribution network in Asia. Mr. Willis was trained as a sonographer and had clinical appointments at the Health Sciences Center and the Misericordia General Hospital in Winnipeg, Man., Canada. He completed business training at Wharton Business School.

Danny Dalla-Longa

Mr. Danny Dalla-Longa is an Independent Director of VentriPoint Diagnostics Ltd. Mr. Dalla-Longa has served on various public company boards of directors and on the audit committees of such boards. Mr. Dalla-Longa holds a Bachelor of Commerce from the University of Calgary, Chartered Business Valuation degree, is a Chartered Accountant and has also been a Senior member of the American Society of Appraisers and a Certified Business Appraiser.

Basic Compensation

Name Fiscal Year Total

George Adams

358,218

Ellen Briant

88,042

Alan Rabinowitz

--

Donald Segal

--

David Willis

--

Danny Dalla-Longa

--
As Of  30 Dec 2013

Options Compensation